Patents by Inventor Edward R. Lee
Edward R. Lee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6323191Abstract: Cystic fibrosis transmembrane conductance regulator (CFTR) is a chloride (Cl−) channel regulated by phosphorylation and intracellular nucleotides. CFTR is the major Cl− transport pathway in airway epithelial cells. The abnormal transepithelial Cl− transport and subsequent defective fluid transport caused by CF is a result of the genetic mutations of the gene coding for the CFTR protein. The present invention is directed to the novel use of ionophores as artificial Cl− transport pathways into CF epithelia to treat the defective Cl− and fluid transport lonophores and in particular, small molecule ionophores, represent a potential novel means of treating CF. The invention also includes using an ionophore to generate chloride secretion on intact monolayers of airway epithelia cells and other epithelia cells by administering an ionophore to a mammal.Type: GrantFiled: June 17, 1999Date of Patent: November 27, 2001Assignee: Genzyme CorporationInventors: David J. Harris, Edward R. Lee, Canwen Jiang, Seng H. Cheng, Mathieu Lane
-
Patent number: 6071890Abstract: Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or acyl groups; and cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile.Type: GrantFiled: October 19, 1995Date of Patent: June 6, 2000Assignee: Genzyme CorporationInventors: Ronald K. Scheule, Rebecca G. Bagley, Simon J. Eastman, Seng H. Cheng, John Marshall, Nelson S. Yew, David J. Harris, Edward R. Lee, Craig S. Siegel
-
Patent number: 5952516Abstract: Cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile.Type: GrantFiled: May 8, 1997Date of Patent: September 14, 1999Assignee: Genzyme CorporationInventors: Craig S. Siegel, Edward R. Lee, David J. Harris
-
Patent number: 5948767Abstract: Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or acyl groups; and cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile.Type: GrantFiled: July 12, 1996Date of Patent: September 7, 1999Assignee: Genzyme CorporationInventors: Ronald K. Scheule, Rebecca G. Bagley, Simon J. Eastman, Seng H. Cheng, John Marshall, Nelson S. Yew, David J. Harris, Edward R. Lee, Craig S. Siegel, Chau-Dung Chang, S. Catherine Hubbard
-
Patent number: 5948925Abstract: Cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile.Type: GrantFiled: May 6, 1997Date of Patent: September 7, 1999Assignee: Genzyme CorporationInventors: Mikaela N. Keynes, Craig S. Siegel, Edward R. Lee, David J. Harris
-
Patent number: 5942634Abstract: Cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile.Type: GrantFiled: May 9, 1997Date of Patent: August 24, 1999Assignee: Genzyme CorporationInventors: Craig S. Siegel, Edward R. Lee, David J. Harris
-
Patent number: 5939401Abstract: Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. By this invention, such cationic amphiphile is used in a state in which it is capable of accepting additional protons, i.e., it is not fully protonated. For purposes of this invention, cationic amphiphiles may be considered to encompass four general categories: (A) T-shaped/steroid-based amphiphiles; (B) T-shaped/non steroid-based amphiphiles; (C) non T-shaped/steroid based amphiphiles and (D) non T-shaped/non steroid-based amphiphiles.Type: GrantFiled: July 15, 1996Date of Patent: August 17, 1999Assignee: Genzyme CorporationInventors: John Marshall, David J. Harris, Edward R. Lee, Craig S. Siegel, Simon J. Eastman, Chau-Dung Chang, Ronald K. Scheule, Seng H. Cheng
-
Patent number: 5935936Abstract: Novel compositions are provided. Typically, the compositions comprise one or more neutral co-lipids and also a cationic amphiphile. Therapeutic compositions are prepared according to the practice of the invention by contacting a therapeutically active molecule with a dispersion of neutral co-lipid(s) and amphiphile(s).Type: GrantFiled: June 3, 1996Date of Patent: August 10, 1999Assignees: Genzyme Corporation, University of IowaInventors: Allen J. Fasbender, Michael J. Welsh, Craig S. Siegel, Edward R. Lee, Chau-Dung Chang, John Marshall, Seng H. Cheng, David J. Harris, Simon J. Eastman, Shirley C. Hubbard, Mathieu B. Lane, Eric A. Rowe, Ronald K. Scheule, Nelson S. Yew
-
Patent number: 5925628Abstract: Cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile.Type: GrantFiled: March 31, 1997Date of Patent: July 20, 1999Assignee: Genzyme CorporationInventors: Edward R. Lee, David J. Harris, Craig S. Siegel
-
Patent number: 5912239Abstract: Cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile.Type: GrantFiled: April 4, 1997Date of Patent: June 15, 1999Assignee: Genzyme CorporationInventors: Craig S. Siegel, Edward R. Lee, David J. Harris
-
Patent number: 5910487Abstract: Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or acyl groups; and cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile.Type: GrantFiled: October 20, 1995Date of Patent: June 8, 1999Assignee: Genzyme CorporationInventors: Nelson S. Yew, Seng H. Cheng, Simon J. Eastman, John Marshall, Ronald K. Scheule, David J. Harris, Edward R. Lee, Craig S. Siegel
-
Patent number: 5840710Abstract: Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or acyl groups; and cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile.Type: GrantFiled: October 20, 1995Date of Patent: November 24, 1998Assignee: Genzyme CorporationInventors: Edward R. Lee, David J. Harris, Craig S. Siegel, Mathieu B. Lane, Shirley C. Hubbard, Seng H. Cheng, Simon J. Eastman, John Marshall, Ronald K. Scheule
-
Patent number: 5783565Abstract: Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or acyl groups; and cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile.Type: GrantFiled: February 1, 1996Date of Patent: July 21, 1998Assignee: Genzyme CorporationInventors: Edward R. Lee, David J. Harris, Craig S. Siegel, Seng H. Cheng, Simon J. Eastman, John Marshall, Ronald K. Scheule
-
Patent number: 5767099Abstract: Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or acyl groups; and cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile.Type: GrantFiled: October 20, 1995Date of Patent: June 16, 1998Assignee: Genzyme CorporationInventors: David J. Harris, Edward R. Lee, Craig S. Siegel, Eric A. Rowe, Shirley C. Hubbard
-
Patent number: 5747471Abstract: Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from ether or ester-linked alkyl groups, and cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile.Type: GrantFiled: October 11, 1995Date of Patent: May 5, 1998Assignee: Genzyme CorporationInventors: Craig S. Siegel, David J. Harris, Edward R. Lee, Shirley C. Hubbard, Seng H. Cheng, Simon J. Eastman, John Marshall, Ronald K. Scheule, Mathieu B. Lane, Eric A. Rowe
-
Patent number: 5719131Abstract: Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or acyl groups; and cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile.Type: GrantFiled: October 20, 1995Date of Patent: February 17, 1998Assignee: Genzyme CorporationInventors: David J. Harris, Edward R. Lee, Craig S. Siegel, Seng H. Cheng, Simon J. Eastman, John Marshall, Ronald K. Scheule
-
Patent number: 5650096Abstract: Novel cationic amphiphiles are provided that facilitate transport of biologically active molecules into cells. Typically, the amphiphiles contain lipophilic groups derived from steroids or from mono or dialkylamines, and two cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles, with or without colipids, and therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, polypeptides and low molecular weight organic compounds. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells.Type: GrantFiled: December 9, 1994Date of Patent: July 22, 1997Assignee: Genzyme CorporationInventors: David J. Harris, Edward R. Lee, Craig S. Siegel, Seng H. Cheng, Simon J. Eastman, John Marshall
-
Patent number: 5582201Abstract: An assembly which includes a valve adapted for connection to a source of pressurized gas having a first connector, a regulator for regulating flow of gas from the source and having a second connector, and an automatic shutoff module positioned in the first connector, the module being adapted to shut off the gas flow in response to certain unsafe conditions, e.g., excess ambient temperatures and/or excess gas flow rates. The second connector includes a probe which is receivable by the first connector, and further includes a connector element that is rotatably mounted on the second connector and adapted to engage the first connector to form a secure interconnection between the first and second connectors. The automatic shutoff module includes an activator housing and an activator movably mounted in the activator housing, the activator being normally closed but being abuttingly held open by the probe upon connection.Type: GrantFiled: November 9, 1994Date of Patent: December 10, 1996Assignee: S. H. Leggitt CompanyInventors: Edward R. Lee, Christopher G. Turney
-
Patent number: D362712Type: GrantFiled: August 22, 1994Date of Patent: September 26, 1995Assignee: S. H. Leggitt CompanyInventor: Edward R. Lee
-
Patent number: D379845Type: GrantFiled: August 22, 1994Date of Patent: June 10, 1997Assignee: S. H. Leggitt CompanyInventor: Edward R. Lee